MRX-6038 (i.e., MRX-5 project of MicuRx Pharmaceuticals R&D pipeline), a novel bacterial leucine-tRNA synthetase inhibitor, is independently developed by MicuRx Pharmaceuticals, and the related research papers on antibacterial activity against Mycobacterium abscessus was published online on August 15, 2022 in Antimicrobial Agents and Chemotherapy, a journal of the American Society of Microbiology, and selected as an Editor's Pick among others. This study was conducted in collaboration with the research group of Professor Chu Haiqing from Shanghai Pulmonary Hospital and Shanghai MicuRx Pharmaceuticals Co., Ltd. By evaluating the in vitro antibacterial activity of MRX-6038 against 12 nontuberculous mycobacteria and 227 clinical isolates, as well as the in vivo efficacy against Mycobacterium abscessus pulmonary infection in mice model, it is demonstrated that MRX-6038 has excellent anti-Mycobacterium abscessus activity, certain synergistic effect with clarithromycin or azithromycin, and good efficacy against intracellular infection and mouse pulmonary infection. This also means that MRX-6038 holds promise as a potential candidate for the treatment of M. abscessus infection. Mycobacterium abscessus, commonly found in soil, dust, and water, is an increasingly recognized human pathogen and is emerging as a major threat. It can lead to a variety of clinical manifestations, and the prevalence is increasing yearly in patient populations…

Recently, with its innovation achievements in the field of anti infection, MicuRx Pharmaceuticals was awarded the "Top 10 New Drug Innovation Companies of the Year" in the "2021 Drug Innovation Award Annual Selection". The "Annual Selection of Drug Innovation Award" is sponsored by the Securities Times. As the mainstream media of the securities market, the Securities Times has long been concerned about and committed to promoting the development of the pharmaceutical industry. Through the selection of China's excellent drug innovation projects, excellent enterprises and outstanding figures, China's innovative drug enterprises and innovative varieties are promoted at home and abroad to promote the improvement of China's drug innovation ability. Since the establishment of MicuRx Pharmaceuticals in 2007, it has adhered to the principle of "Better therapy through superior medicine", and brought products that can better meet clinical needs with rich experience in the research and development of anti infective drugs. In 2021, the MicuRx's blockbuster antimicrobial infection drug, contezolid, was successfully marketed in China and included in the medical insurance in 2022. In May this year, the global phase III clinical trial of MRX-4 for injection and contezolid tablets for sequential treatment of diabetes foot infection started the first patient administration,…

Shanghai MicuRx Pharmaceuticals (Stock code: 688373) has successfully listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange. The company issued 130 million shares to the public at a price of 8.16 yuan per share. The total amount of new shares raised was 1.0608 billion RMB. After the issuance, the total share capital was 655,210,100 shares. The company's main business is to discover, develop and commercialize innovative unmeet clinical drugs . The funds raised this time are mainly used for innovative drug research and development, marketing channel upgrading, academic promotion, supplement of working capital and other projects.

Shanghai, China, and Foster City, US  - May 1, 2022 - Shanghai MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focusing on novel therapeutics for infectious diseases, today announced that the first patient has been enrolled into a diabetic foot infection (DFI) clinical trial with Contezolid Acefosamil (MRX-4) for injection followed by Contezolid tablet at the Harbor-UCLA Medical Center located in Los Angeles. This will be one of the worldwide registration clinical trials for a New Drug Application (NDA) of Contezolid Acefosamil for injection, and will also support the indication expansion of Contezolid tablet. Dr. Zhengyu Yuan, founder and CEO of MicuRx, commented, "This is the first multiregional clinical trial for MicuRx, and it is a key milestone for the globalization of the MicuRx pipeline which will also helps to bring these two innovative drugs to patients globally". This trial is a phase III, multicenter, randomized, double-blinded study to evaluate the safety and efficacy of Contezolid Acefosamil and Contezolid compared to Linezolid administered intravenously and orally in patients with moderate or severe diabetic foot infections. Dr. Edward Fang, Chief Medical Officer of MicuRx further commented, "The phase III DFI study comparing Contezolid Acefosamil/Contezolid to Linezolid will be carried out in more than 70 clinical sites in the US, China, and European countries. The results of the study will be used to support…

SHANGHAI, China– June 2, 2021 MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focused on the discovery, development and commercialization of antibacterial agents against drug-resistant bacterial infection, announced that China National Medical Products Administration (NMPA) has approved its new drug application for contezolid for the treatment of complicated skin and soft tissue infection. Contezolid, designed and developed by MicuRx’s China and US R&D team, is the next-generation oxazolidinone agent against multi-drug resistant (MDR) Gram-positive bacterial infections. Contezolid is the exciting product of the company’s 12 years of effort, which represent a major breakthrough for new the drug discovery to combat infectious diseases in China. By leveraging the proprietary technology platform built for drug discovery and screening, MicuRx R&D team discovered the next-generation oxazolidinone candidate contezolid (formerly named MRX-I) for the treatment of infections caused by Gram-positive bacteria (including multidrug-resistant bacteria) in 2008. Backed by a massive amount of data, the team has confirmed that contezolid has great efficacy in treating infections caused by MDR Gram-positive bacteria, at the meantime significantly reduces the side effects associated with myelosuppression frequently encountered with the type of antibiotics and the tendency to induce drug resistance . MicuRx has successfully completed nine clinical trials of contezolid both in…

On December 21, 2020, Shanghai MicuRx Pharmaceuticals Co., Ltd. announced the completion of round E financing (including new shares and old shares) totaling more than 700 million yuan. This round of financing was led by Junlian Capital, with the participation of several professional institutions including Yingke Capital, Founder Hesheng, China Merchants Securities, Detong Capital, KIP and Zhongtai Venture Capital. The funds will mainly be used to expand the research on indications of new drugs, promote the follow-up international multi center clinical trials, expand the R&D product pipeline, and independently commercialize the Chinese market. As the world's leading anti infective drug R&D technology enterprise, At the beginning of 2020, MicuRx has submitted the marketing application of the first new drug, Contezolid (Youxitai®，MRX-I), in China, which has been included in the priority review and approval. Contezolid is the first class 1 new drug against drug-resistant bacteria independently developed by MicuRx. It can be used to treat infections caused by multiple drug-resistant gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE). Since the discovery of Contezolid in 2008, after 11 years of development, MicuRx completed the world's first phase III clinical trial for complex skin and soft tissue infections in 2019, and is expected…

August 5, 2020, MicuRx Pharmaceuticals, a Biotech focusing on discovery and development of novel antimicrobials, officially announced the close of nearly $43M series D financing, led by Huagai Capital, and with participation from Sinopharm-CICC and Zero2IPO Asset Management. The funds will be mainly used to promote and expand clinical pipeline, and to support the comprehensive independent commercialization in China market. “We are honored to be recognized and supported by the Chinese top investors. Completion of this round marks the official entry of MicuRx into a new stage of development. “said Dr. Yuan Zhengyu, founder and CEO of the company,” The world’s public health system will face unprecedented challenges in 2020. At the same time, the world will continue to face the dual urgency of bacterial resistance and the shortage of new antimicrobial drugs. Shouldering the sacred mission of fighting infection, MicuRx will adhere to the enterprise spirit of “professionalism and innovation”, and strive to bring more original, efficient and safe products to patients with severe infection in China and the world, so as to better benefit the society. ” As the leading investor of this round of financing, Xu Xiaolin, chairman of Huagai Capital, congratulated MicuRx on the successful completion…

SHANGHAI, China, and FOSTER CITY, California, USA – September 19, 2019. MicuRx Pharmaceuticals, Inc., today announced positive top-line results from the pivotal Phase 3 clinical trial in China for its lead antibacterial drug candidate contezolid (MRX-I) in adult patients with complicated skin and soft tissue infection (cSSTI). Contezolid met the primary endpoint of noninferiority compared to linezolid for the clinical cure rate at the test-of-cure visit, and was associated with fewer drug-related hematologic laboratory adverse events. “We are very pleased with the favorable results of this Phase 3 clinical trial which established that contezolid is an effective and safer antibacterial drug,” said Dr. Zhengyu Yuan, President and CEO of MicuRx. “We plan to file a New Drug Application with the National Medical Products Administration (NMPA) of China in the 4th quarter of 2019 for this exciting new drug,” continued Dr. Yuan. Contezolid is an oral oxazolidinone antibiotic designed to treat drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), while offering physicians and patients a new therapeutic option than currently available oxazolidinone agents. The development of contezolid in China has been designated as a “Significant New Drugs Development Special Project”, and contezolid has also been granted QIDP designation…